Claims:

1. An oligopeptidic compound comprising the amino acid sequence set forth in SEQ ID NO: 1, or an amino acid sequence having at least 85 % sequence identity thereto, for use in the treatment of a neoplastic condition, wherein said oligopeptidic compound has activity in inhibiting the growth and/or viability of neoplastic cells and said treatment comprises administering said oligopeptidic compound and a checkpoint inhibitor to a subject.

2. The oligopeptidic compound for use according to claim 1, wherein said oligopeptidic compound comprises or consists of the amino acid sequence set forth in SEQ ID NO: 1.

3. The oligopeptidic compound for use according to claim 1 or 2, wherein said oligopeptidic compound is an inverso-compound, every amino acid of which is a D-amino acid.

4. The oligopeptidic compound for use according to any one of claims 1 to 3, wherein said oligopeptidic compound is selectively cytotoxic towards cancer cells.

5. The oligopeptidic compound for use according to any one of claims 1 to 4, wherein said checkpoint inhibitor blocks the interaction between PD-1 and PD-L1.

6. The oligopeptidic compound for use according to claim 5, wherein said checkpoint inhibitor is an antibody which binds PD-1 or an antibody which binds PD-L1.

7. The oligopeptidic compound for use according to any one of claims 1 to 4, wherein said checkpoint inhibitor blocks the interaction between CTLA-4 and CD80 or CD86.

8. The oligopeptidic compound for use according to claim 7, wherein said checkpoint inhibitor is an antibody which binds CTLA-4.

9. The oligopeptidic compound for use according to any one of claims 1 to 8, wherein said treatment comprises separately, simultaneously or sequentially administering said oligopeptidic compound and said checkpoint inhibitor to said subject.

10. The oligopeptidic compound for use according to any one of claims 1 to 9, wherein said subject is a mammal, preferably a mouse, rat, guinea pig, cat, dog, pig, horse, cow, sheep, goat, monkey or ape.

11. The oligopeptidic compound for use according to claim 10, wherein said subject is a human.

12. The oligopeptidic compound for use according to any one of claims 1 to 11, wherein said neoplastic condition is cancer.

13. The oligopeptidic compound for use according to claim 12, wherein said cancer is cervical cancer, anal cancer, vaginal cancer, vulvar cancer, penile cancer, melanoma, lung cancer, a head and neck cancer, bladder cancer, kidney cancer, Hodgkin's lymphoma, a squamous cell carcinoma or Merkel cell carcinoma.

14. The oligopeptidic compound for use according to claim 12 or 13, wherein said cancer is microsatellite instability-high or mismatch-repair deficient.

15. The oligopeptidic compound for use according to any one of claims 12 to 14, wherein said subject is HPV-positive.

16. A method of treating a neoplastic condition, comprising administering an oligopeptidic compound and a checkpoint inhibitor to a subject in need thereof, wherein said oligopeptidic compound, checkpoint inhibitor, subject, treatment and neoplastic condition are as defined in any one of claims 1 to 15.

17. Use of an oligopeptidic compound in the manufacture of a medicament for treating a neoplastic condition, wherein the treatment of said neoplastic condition comprises administering said medicament and a checkpoint inhibitor to a subject, and said oligopeptidic compound, checkpoint inhibitor, subject, treatment and neoplastic condition are as defined in any one of claims 1 to 15.

18. A kit comprising an oligopeptidic compound as defined in claim 1 and a checkpoint inhibitor.

19. The kit of claim 18, wherein said oligopeptidic compound is as defined in any one of claims 2 to 4 and said checkpoint inhibitor is as defined in any one of claims 5 to 8.

20. A product comprising an oligopeptidic compound as defined in claim 1 and a checkpoint inhibitor for separate, simultaneous or sequential use in the treatment of a neoplastic condition in a subject.

21. The product of claim 20, wherein the oligopeptidic compound, checkpoint inhibitor, neoplastic condition, treatment and subject are as defined in any one of claims 2 to 15.